INTEGRATED IMPACT ASSESSMENT a Telemedicine Program in the Care of Patients With Diabetes Mellitus Type 1 Intensive Treatment With Multiple Daily Injections.

Inclusion Criteria: * Patients with DM1 plus 1 year of evolution. * Age ≥18 and \<65 years. * HbA1c prior to study inclusion\> 7%. * MDI intensive insulin therapy in basal-bolus regimen. * Patients candidates for telemonitoring. Approximately 50% of the patients should work with phone or tablet with Android operating system with active data rate to use wireless solution (bluetooth) OnLine MenaDiab® telemedicine. The remaining patients will work with the USB cable solution telemedicine MenaDiab® OnLine. * Patients who have given written informed consent. Exclusion Criteria: * Treatment with ISCI. * Chronic kidney disease, liver disease, thyroid dysfunction (hypothyroidism except properly treated and controlled). * Pregnant or planning pregnancy. * Diabetes mellitus type 2. * Severe psychological disorders. * Lack of cooperation (informed consent). * Patients who are participating in other clinical studies.